About NYBC Ventures
NYBC Ventures is a venture capital firm founded in 2021. It is primarily based out of Boston, United States. As of Jun 2026, NYBC Ventures is an active investor, having invested in 16 companies, with 2 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series B round of City Therapeutics Overall, NYBC Ventures portfolio has seen 1 acquisition, namely Vega Therapeutics. A lot of funds co-invest with NYBC Ventures, with names like Sofinnova Investments sharing a substantial percentage of its portfolio. NYBC Ventures has team of 4 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Seed & 2 more
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
NYBC Ventures' List of Top Investments
NYBC Ventures has a portfolio of 16 companies. Their most notable investmentis in Functional FluidicsTheir portfolio spans across United States, Germany, Netherlands and 1 more locations. They have invested in Life Sciences, Enterprise Applications, High Tech and 1 other sectors, across stages such as Series B, Seed and 2 more. Here is the list of top investments by NYBC Ventures:
Developer of antibody therapies for multiple diseases. The company is developing antibody drug discovery to generate drug programs that target multiple diseases with a single therapy. Its lead candidate ELA026 is a monoclonal antibody specifically designed to address severe inflammatory disorders. The company is addressing drugs for immunology, immuno-oncology, and rare hematologic diseases.
Key facts about STAR Therapeutics
- Founded Year: 2018
- Location: San Francisco (United States)
- Stage: Series D
- Total Funding till date: $215M
- Employee Count: 60 as on Jun 30, 2026
- Investors: Frazier Life Sciences, Redmile Group and 18 Others
- Latest Funding Round: Series D, Sep 30, 2025, $*****
- Highlight: Editors' Pick
2. Vitestro
Developed AI-based blood drawing robot for clinic use. The company has developed a medical robotics device that autonomously draws blood from patients. The device has a guided 3D construction with a robotic needle that secures blood collection. It has features for bandage application as well.
Key facts about Vitestro
- Founded Year: 2017
- Location: Utrecht (Netherlands)
- Stage: Series B
- Total Funding till date: $120M
- Employee Count: 138 as on Jul 31, 2026
- Investors: PGGM, Mayo Clinic and 13 Others
- Latest Funding Round: Series B, Mar 10, 2026, $*****
- Highlight: Editors' Pick
Developer of gene therapies for multiple diseases. It offers RNAi therapeutics based on next-generation engineering of small interfering RNAs for patients across multiple disease indications.
Key facts about City Therapeutics
- Founded Year: 2006
- Location: Cambridge (United States)
- Stage: Series B
- Total Funding till date: $234M
- Employee Count: 85 as on Jul 31, 2026
- Investors: Fidelity Investments, Rock Springs Capital and 9 Others
- Latest Funding Round: Series B, Jun 08, 2026, $*****
- Highlight: Editors' Pick
_1568087563364.png?format=webp&height=120&width=120){kind=logo}
Veralox Therapeutics is developing small molecule therapeutics for targeting pathways related to the pathologies of thrombosis and type 1 diabetes. The company is developing small molecules to target arachidonic acid (AA) pathway protein 12-lipoxygenase required for the production of 12-HETE involved in the development of multiple diseases.
Key facts about Veralox Therapeutics
- Founded Year: 2017
- Location: Frederick (United States)
- Stage: Series B
- Total Funding till date: $47.5M
- Employee Count: 6 as on Dec 31, 2021
- Investors: Sanofi Ventures, TEDCO and 13 Others
- Latest Funding Round: Series B, Jun 21, 2023, $*****
- Highlight: Editors' Pick
5. Thymmune
Developer of immunetherapeutics for immune-disorders. It offers iPSC-derived thymic cells -based therapeutics to restore normal immune function and treat immunodeficiencies, transplant-related, and autoimmune disorders.
Key facts about Thymmune
- Founded Year: 2019
- Location: Cambridge (United States)
- Stage: Seed
- Total Funding till date: $7M
- Employee Count: 25 as on Jul 31, 2026
- Investors: Pillar VC, HHS and 6 Others
- Latest Funding Round: Grant (prize money), Apr 28, 2025, $*****
- Highlight: Editors' Pick
NYBC Ventures' Year-on-Year Investment Trends
NYBC Ventures has invested in 16 companies over the last 4 years, with an average of 3 new investments annually in the last 3 years. In 2025, it made 3 investments, while as of Jun 2026, it has made 2 investments in this year. Its most recent first time investment was in City Therapeutics and most recent follow-on round was in Vitestro.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 1 | 2 |
2025 | 2 | 1 | 3 |
2024 | 4 | 0 | 4 |
2023 | 5 | 0 | 5 |
2022 | 1 | 0 | 1 |
NYBC Ventures' Investments by Stage
NYBC Ventures has made 5 investments in Series B stage with an average round size of $50M, 3 investments in Seed stage with an average round size of $7M, 3 investments in Series A stage with an average round size of $31M and 2 investments in Series C stage with an average round size of $55M.Stage of entry | No. of Investments |
|---|---|
Series B | 5 |
Seed | 3 |
Series A | 3 |
Series C | 2 |
Note: We have considered here, only first round of investments
NYBC Ventures' Investments by Sector
NYBC Ventures has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, High Tech and Robotics - Industry Applications. Notably, it has invested in 15 Tech companies, 14 Enterprise (B2B) companies, 3 Software companies and at least 3 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 13 |
Enterprise Applications | 2 |
High Tech | 1 |
Robotics - Industry Applications | 1 |
Note: We have considered here, only first round of investments
NYBC Ventures' Investments by Geography
NYBC Ventures has made most investments in United States (11), followed by Germany where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 11 |
Germany | 1 |
Netherlands | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
NYBC Ventures' recent investments
NYBC Ventures has made 2 investments in 2026 so far - City Therapeutics and Vitestro.Here are the most recent investments by NYBC Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 08, 2026 | United States | Series B | 1542 | [+9] | |
Mar 10, 2026 | Netherlands | Series B | 5326 | [+11] | |
Dec 09, 2025 | United Kingdom | Series A | 3422 | [+3] | |
Sep 30, 2025 | United States | Series D | 4461 | [+15] | |
Apr 11, 2025 | United States | Series C | 1962 |
Acquired companies in NYBC Ventures' Portfolio
1 company from NYBC Ventures' portfolio has been acquired. The most recent acquisition was Vega Therapeutics in Jun 2026 by Incyte for $*****.Here are NYBC Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 08, 2026 | - | - | 2377 |
Team profile of NYBC Ventures
NYBC Ventures has a team of 4 members including 2 Partners located in United States. NYBC Ventures' team does not sit on the board of any company as of now.Co-investors of NYBC Ventures
Over the past 4 years, 104 investors have co-invested in NYBC Ventures's portfolio companies. This includes funds and angels.
- Invested before NYBC Ventures: HHS, Europa and 48 others have invested in rounds before NYBC Ventures. There are 6 companies where HHS has invested before NYBC Ventures and 2 companies where Europa has invested before NYBC Ventures.
- Top Co-investors of NYBC Ventures: 38 investors entered a company along with NYBC Ventures. These include investors like Sofinnova Investments (2 companies).
- Invested after NYBC Ventures: A total of 16 investors have invested in NYBC Ventures's portfolio after their investments. Top Investors include Sanofi Ventures (1 company), Viking Global Investors (1 company) and Janus Henderson Investors (1 company).
Recent News related to NYBC Ventures
•
City Therapeutics Secures $99.5M Series B for RNAiVentureburn•Jun 09, 2026•City Therapeutics, NYBC Ventures, Regeneron Ventures, Rock Springs Capital and 6 others
•
City Therapeutics Secures $99.5M Series B Funding to Advance RNAi PipelineBioSpace•Jun 08, 2026•City Therapeutics, NYBC Ventures, Viking Global Investors, Casdin Capital and 1 other
•
Utrecht-based Robot Blood Sampler Raises 60 MillionMena•Mar 10, 2026•InterVest, Vitestro, PGGM, LabCorp and 9 others
•
Cellular Origins Completes $40M Series A RoundContract Pharma•Dec 09, 2025•Cellular Origins, TTP Group, Highland Europe, BGF and 3 others
•
•
AvenCell: Clinical-Stage Cell Therapy Company Raises $112 Million (Series B)Pulse 2.0•Nov 04, 2024•AvenCell, Novo Holdings, F-Prime Capital, Eight Roads Ventures and 3 others
•
AvenCell Raises $112 Million in Series B; Funding Led by Novo HoldingsPR Newswire•Oct 22, 2024•AvenCell, Novo Holdings, Blackstone, NYBC Ventures and 5 others
•
AvenCell secures $112M series B to flick 'switchable' CAR-Ts in the clinicFierce Biotech•Oct 21, 2024•AvenCell, Novo Holdings, Blackstone, F-Prime Capital and 3 others
•
Vitestro Gains $22 Million for Autonomous Blood Draw DeviceMedical Product Outsourcing•May 02, 2024•Vitestro, Invest-NL, NYBC Ventures, Sonder Capital and 3 others
•
Aronora Raises Investment from NYBC VenturesFinSMEs•Oct 16, 2023•Aronora, NYBC Ventures, NYBC Ventures
